Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 1

Conditions

Thyroid Neoplasms 2Thyroid Cancer, Papillary 1Neoplasm Metastasis 1Adenocarcinoma, Follicular 1

Interventions

Specimen Handling 265Magnetic Resonance Spectroscopy 216pembrolizumab 212Carboplatin 173Biopsy 162Cisplatin 155Nivolumab 147Cyclophosphamide 131Paclitaxel 116Radiotherapy 115Gemcitabine 110Bevacizumab 91durvalumab 84Dexamethasone 79Rituximab 74Oxaliplatin 71atezolizumab 67Fluorouracil 66Doxorubicin 65Capecitabine 65Docetaxel 64venetoclax 63Etoposide 63Radiosurgery 58Radiation 57Prednisone 55Ipilimumab 55Cytarabine 55Pemetrexed 54Lenalidomide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Iodine-131 × 90 days × Clear all
NCT03841617 2026-06-05

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
30 enrolled
Head & Neck

Neoplasm Metastasis, Thyroid Neoplasms

NCT02152995 2026-04-13

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
34 enrolled 18 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡